OctoPlus wins expansion of drug delivery evaluation contract with existing client
OctoPlus N.V. announced that it has won an expansion of a drug delivery technology evaluation contract with an existing client, a global pharmaceutical company. In 2008 and 2009 OctoPlus performed preliminary feasibility work for this client and with the results from these studies the client has decided to proceed with the evaluation of OctoPlus' technology for a product candidate in its pipeline.
In October last year OctoPlus announced a strategic focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing. This is the fourth compound in 2009 for which OctoPlus will work on a controlled release formulation.
Under the contract OctoPlus will evaluate the feasibility of a controlled release formulation that combines the client's product candidate with OctoPlus' proprietary drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
US Government Exercises Next Part of Bavarian Nordic's Freeze-Dried IMVAMUNE Contract
Oral_contraceptive_formulations

Frosty hydrogen as target - New method improves proton acceleration with high power laser
Francis_Collins_(geneticist)
Amorfix detects vCJD prions in blood from non-human primates
Cashew
Colitis in infants caused by their own intestinal flora?

What makes erionite carcinogenic? - Mineralogists provide new findings on carcinogenic silicate
Creutzfeldt-Jakob_disease

Second-Generation COVID-19 Vaccine Candidate Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study - Fast onset of strong neutralizing antibody titers after first vaccination
Pfizer Provides Update on Two R&D Pipeline Developments
